Navigation Links
Cepheid Welcomes Senior Vice President of Human Resources

SUNNYVALE, Calif., Jan. 17, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Mike Fitzgerald to the position of Senior Vice President, Human Resources, effective January 14, 2012. 

Mr. Fitzgerald joins Cepheid from Verigy, Inc., a wholly owned subsidiary of Advantest Corp., where he most recently served as Senior Vice President of Human Resources.  Prior to Verigy, Mr. Fitzgerald was Vice President of Human Resources at Varian, Inc. where he was responsible for the development and implementation of a global human resources program in support of the company's corporate goals for approximately 3,500 employees worldwide.  In total, Mr. Fitzgerald brings more than two decades of broad human resources experience to Cepheid, including Vodafone, PLC, and Xerox Financial Services.

In connection with his employment, the Compensation Committee of Cepheid's Board of Directors has granted Mr. Fitzgerald an option to purchase 56,000 shares of Cepheid common stock at the closing price of Cepheid common stock on Mr. Fitzgerald's employment commencement date and restricted stock units in respect of 10,000 shares of Cepheid common stock.  The option will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of grant and ratably monthly thereafter, and will expire after seven years from the grant date, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The restricted stock units will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of the grant and as to an additional 1/16th of the restricted stock units at the end of each three-month period thereafter, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The option and restricted stock units were granted as inducement grants pursuant to Section 5635(c)(4) of The NASDAQ Stock Market Rules.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Jacquie RossCepheid Corporate Communications

Cepheid Investor RelationsTel: (408) 400 8377

Tel: (408) 400" target="_blank">


SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
2. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
5. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
6. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
7. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
8. Cepheid Reports 2009 First Quarter Results
9. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
10. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
11. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
(Date:11/24/2015)... ... 24, 2015 , ... Copper is an essential micronutrient that ... proteins, copper is also toxic to cells. With a $1.3 million award from ... conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP and ... to develop and pitch their BIG ideas to improve health and wellness in their ... votes to win the title of SAP's Teen Innovator, an all-expenses paid trip to ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
(Date:10/27/2015)... Calif. , Oct. 27, 2015 Synaptics Inc. ... solutions, today announced that Google has adopted the Synaptics ... touch controller solutions to power its newest flagship smartphones, ... by Huawei. --> ... like Google to provide strategic collaboration in the joint ...
Breaking Biology News(10 mins):